{"id":"https://openalex.org/W2004633003","doi":"https://doi.org/10.1158/1538-7445.am2011-5499","title":"Abstract 5499: Temozolomide (TMZ) cytotoxicity in human melanoma cell lines is enhanced by concomitant treatment with the histone deacetylase (HDAC) inhibitor vorinostat (SAHA) and PARP inhibitor MK-4827","display_name":"Abstract 5499: Temozolomide (TMZ) cytotoxicity in human melanoma cell lines is enhanced by concomitant treatment with the histone deacetylase (HDAC) inhibitor vorinostat (SAHA) and PARP inhibitor MK-4827","publication_year":2011,"publication_date":"2011-04-01","ids":{"openalex":"https://openalex.org/W2004633003","doi":"https://doi.org/10.1158/1538-7445.am2011-5499","mag":"2004633003"},"language":"en","primary_location":{"id":"doi:10.1158/1538-7445.am2011-5499","doi":"https://doi.org/10.1158/1538-7445.am2011-5499","is_oa":false,"landing_page_url":"https://doi.org/10.1158/1538-7445.am2011-5499","pdf_url":null,"source":{"id":"https://openalex.org/S168522863","display_name":"Cancer Research","issn_l":"0008-5472","issn":["0008-5472","1538-7445"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","doyens","jufo-3","ki-jl-3","medline","norway-2","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320273","host_organization_name":"American Association for Cancer Research","host_organization_lineage":["https://openalex.org/P4310320273"],"host_organization_lineage_names":["American Association for Cancer Research"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Cancer Research","raw_type":"journal-article"},"volume":null,"type":"conference-abstract","is_traditional":false,"indexed_in":["crossref"],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5056045921","display_name":"Hussein Abdul-Hassan Tawbi","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210128526","display_name":"UPMC Hillman Cancer Center","ror":"https://ror.org/03bw34a45","country_code":"US","type":"facility","lineage":["https://openalex.org/I170201317","https://openalex.org/I4210128526"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Hussein Tawbi","raw_affiliation_strings":["1Univ. of Pittsburgh Cancer Inst., Pittsburgh, PA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"1Univ. of Pittsburgh Cancer Inst., Pittsburgh, PA","institution_ids":["https://openalex.org/I4210128526"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5007239425","display_name":"John M. Kirkwood","orcid":"https://orcid.org/0000-0002-3570-4476","observed_orcids":["https://orcid.org/0000-0002-3570-4476"]},"institutions":[{"id":"https://openalex.org/I4210128526","display_name":"UPMC Hillman Cancer Center","ror":"https://ror.org/03bw34a45","country_code":"US","type":"facility","lineage":["https://openalex.org/I170201317","https://openalex.org/I4210128526"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"John M. Kirkwood","raw_affiliation_strings":["1Univ. of Pittsburgh Cancer Inst., Pittsburgh, PA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"1Univ. of Pittsburgh Cancer Inst., Pittsburgh, PA","institution_ids":["https://openalex.org/I4210128526"]}]},{"author_position":"middle","author":{"id":null,"display_name":"Ying-Chih Lin","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210128526","display_name":"UPMC Hillman Cancer Center","ror":"https://ror.org/03bw34a45","country_code":"US","type":"facility","lineage":["https://openalex.org/I170201317","https://openalex.org/I4210128526"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Ying-Chih Lin","raw_affiliation_strings":["1Univ. of Pittsburgh Cancer Inst., Pittsburgh, PA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"1Univ. of Pittsburgh Cancer Inst., Pittsburgh, PA","institution_ids":["https://openalex.org/I4210128526"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5072864650","display_name":"Shama C. Buch","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I170201317","display_name":"University of Pittsburgh","ror":"https://ror.org/01an3r305","country_code":"US","type":"education","lineage":["https://openalex.org/I170201317"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Shama C. Buch","raw_affiliation_strings":["2Department of Medicine, University of Pittsburgh, Pittsburgh, PA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"2Department of Medicine, University of Pittsburgh, Pittsburgh, PA","institution_ids":["https://openalex.org/I170201317"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5115589745","display_name":"Yan Lin","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210128526","display_name":"UPMC Hillman Cancer Center","ror":"https://ror.org/03bw34a45","country_code":"US","type":"facility","lineage":["https://openalex.org/I170201317","https://openalex.org/I4210128526"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Yan Lin","raw_affiliation_strings":["1Univ. of Pittsburgh Cancer Inst., Pittsburgh, PA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"1Univ. of Pittsburgh Cancer Inst., Pittsburgh, PA","institution_ids":["https://openalex.org/I4210128526"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5048503775","display_name":"Lyubov Kublo","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210128526","display_name":"UPMC Hillman Cancer Center","ror":"https://ror.org/03bw34a45","country_code":"US","type":"facility","lineage":["https://openalex.org/I170201317","https://openalex.org/I4210128526"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Lyubov Kublo","raw_affiliation_strings":["1Univ. of Pittsburgh Cancer Inst., Pittsburgh, PA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"1Univ. of Pittsburgh Cancer Inst., Pittsburgh, PA","institution_ids":["https://openalex.org/I4210128526"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5027371881","display_name":"Jan Hendrik Beumer","orcid":"https://orcid.org/0000-0002-8978-9401","observed_orcids":["https://orcid.org/0000-0002-8978-9401"]},"institutions":[{"id":"https://openalex.org/I170201317","display_name":"University of Pittsburgh","ror":"https://ror.org/01an3r305","country_code":"US","type":"education","lineage":["https://openalex.org/I170201317"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Jan H. Beumer","raw_affiliation_strings":["3Department of Pharmaceutical Sciences, School of Pharmacy, Pittsburgh, PA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"3Department of Pharmaceutical Sciences, School of Pharmacy, Pittsburgh, PA","institution_ids":["https://openalex.org/I170201317"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5113786887","display_name":"Merrill J. Egorin","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210128526","display_name":"UPMC Hillman Cancer Center","ror":"https://ror.org/03bw34a45","country_code":"US","type":"facility","lineage":["https://openalex.org/I170201317","https://openalex.org/I4210128526"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Merrill J. Egorin","raw_affiliation_strings":["1Univ. of Pittsburgh Cancer Inst., Pittsburgh, PA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"1Univ. of Pittsburgh Cancer Inst., Pittsburgh, PA","institution_ids":["https://openalex.org/I4210128526"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5083512608","display_name":"Edward Chu","orcid":"https://orcid.org/0000-0002-0908-5325","observed_orcids":["https://orcid.org/0000-0002-0908-5325"]},"institutions":[{"id":"https://openalex.org/I4210128526","display_name":"UPMC Hillman Cancer Center","ror":"https://ror.org/03bw34a45","country_code":"US","type":"facility","lineage":["https://openalex.org/I170201317","https://openalex.org/I4210128526"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Edward Chu","raw_affiliation_strings":["1Univ. of Pittsburgh Cancer Inst., Pittsburgh, PA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"1Univ. of Pittsburgh Cancer Inst., Pittsburgh, PA","institution_ids":["https://openalex.org/I4210128526"]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5000004904","display_name":"Pamela A. Hershberger","orcid":"https://orcid.org/0000-0003-0030-6520","observed_orcids":["https://orcid.org/0000-0003-0030-6520"]},"institutions":[{"id":"https://openalex.org/I170201317","display_name":"University of Pittsburgh","ror":"https://ror.org/01an3r305","country_code":"US","type":"education","lineage":["https://openalex.org/I170201317"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Pamela Hershberger","raw_affiliation_strings":["4Department of Pharmacology and Chemical Biology, School of Medicine, Pittsburgh, PA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"4Department of Pharmacology and Chemical Biology, School of Medicine, Pittsburgh, PA","institution_ids":["https://openalex.org/I170201317"]}]}],"institutions":[],"countries_distinct_count":1,"institutions_distinct_count":2,"corresponding_author_ids":[],"corresponding_institution_ids":[],"apc_list":null,"apc_paid":null,"fwci":null,"has_fulltext":false,"cited_by_count":0,"citation_normalized_percentile":null,"cited_by_percentile_year":null,"biblio":{"volume":"71","issue":"8_Supplement","first_page":"5499","last_page":"5499"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T11914","display_name":"PARP inhibition in cancer therapy","score":0.9330999851226807,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T11914","display_name":"PARP inhibition in cancer therapy","score":0.9330999851226807,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T11736","display_name":"Histone Deacetylase Inhibitors Research","score":0.018300000578165054,"subfield":{"id":"https://openalex.org/subfields/1312","display_name":"Molecular Biology"},"field":{"id":"https://openalex.org/fields/13","display_name":"Biochemistry, Genetics and Molecular Biology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},{"id":"https://openalex.org/T11533","display_name":"Melanoma and MAPK Pathways","score":0.006899999920278788,"subfield":{"id":"https://openalex.org/subfields/1312","display_name":"Molecular Biology"},"field":{"id":"https://openalex.org/fields/13","display_name":"Biochemistry, Genetics and Molecular Biology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/temozolomide","display_name":"temozolomide","score":0.9990000128746033},{"id":"https://openalex.org/keywords/vorinostat","display_name":"vorinostat","score":0.9879999756813049},{"id":"https://openalex.org/keywords/parp-inhibitors","display_name":"PARP inhibitors","score":0.7910000085830688},{"id":"https://openalex.org/keywords/histone-deacetylase-inhibitors","display_name":"histone deacetylase inhibitors","score":0.9570000171661377},{"id":"https://openalex.org/keywords/melanoma","display_name":"melanoma","score":0.8859999775886536},{"id":"https://openalex.org/keywords/combination-therapy","display_name":"combination therapy","score":0.675000011920929},{"id":"https://openalex.org/keywords/cytotoxicity","display_name":"cytotoxicity","score":0.7039999961853027},{"id":"https://openalex.org/keywords/dna-damage","display_name":"DNA damage","score":0.6119999885559082},{"id":"https://openalex.org/keywords/dna-repair","display_name":"DNA repair","score":0.5460000038146973},{"id":"https://openalex.org/keywords/drug-resistance","display_name":"drug resistance","score":0.5260000228881836},{"id":"https://openalex.org/keywords/a375-cells","display_name":"A375 cells","score":0.796999990940094},{"id":"https://openalex.org/keywords/alkylating-agents","display_name":"alkylating agents","score":0.6869999766349792},{"id":"https://openalex.org/keywords/metastatic-melanoma","display_name":"metastatic melanoma","score":0.7450000047683716},{"id":"https://openalex.org/keywords/radiosensitization","display_name":"radiosensitization","score":0.6060000061988831},{"id":"https://openalex.org/keywords/chemosensitization","display_name":"chemosensitization","score":0.7509999871253967},{"id":"https://openalex.org/keywords/triple-drug-combination","display_name":"triple-drug combination","score":0.4259999990463257}],"concepts":[{"id":"https://openalex.org/C109316439","wikidata":"https://www.wikidata.org/wiki/Q246181","display_name":"Cytotoxicity","level":3,"score":0.8818749189376831},{"id":"https://openalex.org/C2776262904","wikidata":"https://www.wikidata.org/wiki/Q905901","display_name":"Vorinostat","level":5,"score":0.8580707311630249},{"id":"https://openalex.org/C2777389519","wikidata":"https://www.wikidata.org/wiki/Q425088","display_name":"Temozolomide","level":3,"score":0.7496433258056641},{"id":"https://openalex.org/C2779138821","wikidata":"https://www.wikidata.org/wiki/Q7118227","display_name":"PARP inhibitor","level":5,"score":0.7415232062339783},{"id":"https://openalex.org/C98274493","wikidata":"https://www.wikidata.org/wiki/Q128406","display_name":"Pharmacology","level":1,"score":0.5089771747589111},{"id":"https://openalex.org/C2776202225","wikidata":"https://www.wikidata.org/wiki/Q3569101","display_name":"Histone deacetylase inhibitor","level":5,"score":0.5030526518821716},{"id":"https://openalex.org/C2778305200","wikidata":"https://www.wikidata.org/wiki/Q174378","display_name":"Histone deacetylase","level":4,"score":0.47624993324279785},{"id":"https://openalex.org/C53227056","wikidata":"https://www.wikidata.org/wiki/Q189152","display_name":"Viability assay","level":3,"score":0.47595760226249695},{"id":"https://openalex.org/C2777658100","wikidata":"https://www.wikidata.org/wiki/Q180614","display_name":"Melanoma","level":2,"score":0.44119423627853394},{"id":"https://openalex.org/C185592680","wikidata":"https://www.wikidata.org/wiki/Q2329","display_name":"Chemistry","level":0,"score":0.4246911108493805},{"id":"https://openalex.org/C207001950","wikidata":"https://www.wikidata.org/wiki/Q141124","display_name":"In vivo","level":2,"score":0.4220818877220154},{"id":"https://openalex.org/C143425029","wikidata":"https://www.wikidata.org/wiki/Q5205747","display_name":"DNA damage","level":3,"score":0.4152037799358368},{"id":"https://openalex.org/C502942594","wikidata":"https://www.wikidata.org/wiki/Q3421914","display_name":"Cancer research","level":1,"score":0.3980643153190613},{"id":"https://openalex.org/C182979987","wikidata":"https://www.wikidata.org/wiki/Q3907241","display_name":"Poly ADP ribose polymerase","level":4,"score":0.32937130331993103},{"id":"https://openalex.org/C202751555","wikidata":"https://www.wikidata.org/wiki/Q221681","display_name":"In vitro","level":2,"score":0.30134516954421997},{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.2846214473247528},{"id":"https://openalex.org/C86803240","wikidata":"https://www.wikidata.org/wiki/Q420","display_name":"Biology","level":0,"score":0.23045095801353455},{"id":"https://openalex.org/C55493867","wikidata":"https://www.wikidata.org/wiki/Q7094","display_name":"Biochemistry","level":1,"score":0.1673712134361267},{"id":"https://openalex.org/C64927066","wikidata":"https://www.wikidata.org/wiki/Q36293","display_name":"Histone","level":3,"score":0.16065672039985657},{"id":"https://openalex.org/C552990157","wikidata":"https://www.wikidata.org/wiki/Q7430","display_name":"DNA","level":2,"score":0.13305330276489258},{"id":"https://openalex.org/C2778227246","wikidata":"https://www.wikidata.org/wiki/Q1365309","display_name":"Glioma","level":2,"score":0.06983652710914612},{"id":"https://openalex.org/C150903083","wikidata":"https://www.wikidata.org/wiki/Q7108","display_name":"Biotechnology","level":1,"score":0.0},{"id":"https://openalex.org/C82381507","wikidata":"https://www.wikidata.org/wiki/Q416878","display_name":"Polymerase","level":3,"score":0.0}],"mesh":[],"locations_count":1,"locations":[{"id":"doi:10.1158/1538-7445.am2011-5499","doi":"https://doi.org/10.1158/1538-7445.am2011-5499","is_oa":false,"landing_page_url":"https://doi.org/10.1158/1538-7445.am2011-5499","pdf_url":null,"source":{"id":"https://openalex.org/S168522863","display_name":"Cancer Research","issn_l":"0008-5472","issn":["0008-5472","1538-7445"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","doyens","jufo-3","ki-jl-3","medline","norway-2","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320273","host_organization_name":"American Association for Cancer Research","host_organization_lineage":["https://openalex.org/P4310320273"],"host_organization_lineage_names":["American Association for Cancer Research"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Cancer Research","raw_type":"journal-article"}],"best_oa_location":null,"sustainable_development_goals":[{"score":0.98580002784729,"display_name":"Good health and well-being","id":"https://metadata.un.org/sdg/3"}],"study_designs":[],"awards":[],"funders":[],"has_content":{"grobid_xml":false,"pdf":false},"content_urls":null,"referenced_works_count":0,"referenced_works":[],"related_works":["https://openalex.org/W2007591444","https://openalex.org/W4381337323","https://openalex.org/W2318809664","https://openalex.org/W6964068495","https://openalex.org/W2117006689","https://openalex.org/W3000154351","https://openalex.org/W2170176648","https://openalex.org/W3088357215","https://openalex.org/W1995069648","https://openalex.org/W3010095359"],"abstract_inverted_index":{"Abstract":[0],"Introduction:":[1],"TMZ":[2,29,68,136,152,161,178,191,217,232,248],"is":[3,39],"a":[4,227],"non-classical":[5],"alkylating":[6],"agent":[7],"that":[8,47],"induces":[9],"DNA":[10,22,56],"damage":[11,57],"leading":[12],"to":[13,54,112,229],"cytotoxicity,":[14],"with":[15,25,50,162,196,239,244],"modest":[16],"clinical":[17,43],"activity":[18],"in":[19,31,34,42,83,100,124,137,141,154,171,181,186,194,206,210,269],"metastatic":[20,291],"melanoma.":[21,292],"repair":[23],"modulation":[24],"PARP":[26,64,224,243],"inhibitors":[27],"enhances":[28],"cytotoxicity":[30,134,153,173,249],"vitro":[32],"and":[33,36,58,76,91,110,146,166,183,208,218,241,272],"vivo,":[35],"this":[37,277],"strategy":[38,228],"being":[40],"investigated":[41],"trials.":[44],"We":[45,258],"hypothesized":[46],"HDAC":[48,238],"inhibition":[49,225,236],"SAHA":[51,165,198,240],"would":[52],"lead":[53],"increased":[55,132],"potentiate":[59],"the":[60,63,84,94,120,133,213,262,266,274,282,285,302,307],"effect":[61],"of":[62,88,135,160,177,216,237,242,254,265,284,301,306],"inhibitor":[65],"MK-4827":[66,92,128,149,169,245],"on":[67],"cytotoxicity.":[69],"Methods:":[70],"Human":[71],"melanoma":[72,231],"cell":[73,156,202],"lines":[74],"A375":[75,142,207],"FEMX-1":[77,138,182,211],"were":[78,81,117],"used.":[79],"Cells":[80],"treated":[82],"absence":[85],"or":[86,193,199],"presence":[87],"TMZ,":[89],"SAHA,":[90],"at":[93,119,129,174,219,250],"indicated":[95,123],"concentrations":[96,122],"for":[97,290,310],"72":[98],"hr":[99],"96-well":[101],"plates.":[102],"Cell":[103],"viability":[104],"was":[105,204],"determined":[106],"using":[107],"MTS":[108],"assays":[109],"normalized":[111],"vehicle-treated":[113],"control":[114],"cells.":[115],"Drugs":[116],"used":[118],"final":[121],"Table":[125],"1.":[126],"Results:":[127],"10":[130],"nM":[131,148,168],"but":[139],"not":[140],"cells,":[143],"however":[144],"100":[145],"200":[147,167],"moderately":[150],"potentiated":[151],"both":[155],"lines.":[157],"The":[158,234],"combination":[159,195,288],"1":[163],"\u00b5M":[164],"resulted":[170],"profound":[172],"reduced":[175],"doses":[176,253],"(0.2":[179],"mM":[180,185],"1.0":[184],"A375),":[187],"much":[188],"lower":[189],"than":[190],"alone":[192],"either":[197],"MK-4827.":[200],">80%":[201],"kill":[203],"achieved":[205],">95%":[209],"near":[212],"IC50":[214],"concentration":[215],"clinically":[220,251],"achievable":[221,252],"concentrations.":[222],"Conclusion:":[223],"offers":[226],"reverse":[230],"resistance.":[233],"concomitant":[235],"profoundly":[246],"enhanced":[247],"all":[255],"3":[256,267],"agents.":[257],"are":[259],"presently":[260],"optimizing":[261],"dosing":[263],"schedules":[264],"drugs":[268],"preclinical":[270],"models":[271],"investigating":[273],"mechanism(s)":[275],"underlying":[276],"potentiation.":[278],"These":[279],"findings":[280],"support":[281],"investigation":[283],"triple":[286],"drug":[287],"(TMZ+SAHA+MK-4827)":[289],"Citation":[293],"Format:":[294],"{Authors}.":[295],"{Abstract":[296],"title}":[297],"[abstract].":[298],"In:":[299],"Proceedings":[300],"102nd":[303],"Annual":[304],"Meeting":[305],"American":[308],"Association":[309],"Cancer":[311,321],"Research;":[312],"2011":[313],"Apr":[314],"2-6;":[315],"Orlando,":[316],"FL.":[317],"Philadelphia":[318],"(PA):":[319],"AACR;":[320],"Res":[322],"2011;71(8":[323],"Suppl):Abstract":[324],"nr":[325],"5499.":[326],"doi:10.1158/1538-7445.AM2011-5499":[327]},"counts_by_year":[],"updated_date":"2026-09-27T08:07:27.782135","created_date":"2016-06-24T00:00:00"}